XML 116 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net loss $ (196,620) $ (139,311) $ (157,945)
Adjustments to reconcile net loss to cash flows from operating activities:      
Depreciation and amortization 80,413 103,660 98,523
Share-based compensation expense 100,977 105,357 83,917
Deferred income taxes (319) 10,623 7,234
Change in the fair value of contingent consideration 22,800 19,600 (21,600)
Loss on debt refinancing   2,298  
Payment made for debt refinancing   (2,251)  
Impairment of property, plant and equipment   5,746  
Impairment of investment in Synchronicity Pharma, Inc.     10,471
Other non-cash charges (580)    
Other non-cash charges   979 3,471
Changes in assets and liabilities, excluding the effect of acquisitions:      
Receivables 35,136 (58,632) (42,489)
Contract assets (5,156) 880  
Inventory (13,077) (2,665) (30,191)
Prepaid expenses and other assets (1,784) (5,990) (9,506)
Right-of-use assets 8,399    
Accounts payable and accrued expenses 34,847 46,739 72,658
Contract liabilities 16,140 3,252 (1,447)
Operating lease liabilities (9,117)    
Other long-term liabilities 18 8,996 6,094
Cash flows provided by operating activities 72,077 99,281 19,190
CASH FLOWS FROM INVESTING ACTIVITIES:      
Additions of property, plant and equipment (90,942) (69,431) (51,300)
Proceeds from the sale of equipment 900 507 162
Proceeds from contingent consideration 10,000    
Purchases of investments (277,518) (397,727) (431,712)
Sales and maturities of investments 224,602 444,456 464,494
Acquisition of Rodin Therapeutics, Inc.'s net assets, net of cash acquired (8,875)    
Cash flows used in investing activities (141,833) (22,195) (18,356)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Proceeds from the issuance of ordinary shares under share-based compensation arrangements 18,925 20,877 23,517
Employee taxes paid related to net share settlement of equity awards (9,317) (19,622) (16,433)
Principal payments of long-term debt (2,843) (743)  
Payment made for debt refinancing   (2,132) (3,000)
Cash flows provided by (used in) financing activities 6,765 (1,620) 4,084
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (62,991) 75,466 4,918
CASH AND CASH EQUIVALENTS—Beginning of period 266,762 191,296 186,378
CASH AND CASH EQUIVALENTS—End of period 203,771 266,762 191,296
SUPPLEMENTAL CASH FLOW DISCLOSURE:      
Cash paid for interest 13,254 12,526 11,143
Cash paid for taxes 2,508 754 2,992
Non-cash investing and financing activities:      
Purchased capital expenditures included in accounts payable and accrued expenses $ 13,789 $ 11,720 $ 11,151